JOHNSON & JOHNSON is 100.2x more valuable than Mirum Pharmaceuticals, Inc. by market capitalization ($574.10 B vs $5.73 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MIRM | JNJ |
|---|---|---|
| Market cap | $5.73 B | $574.10 B |
| US-listed rank | #1294 | #20 |
| Revenue (latest FY) | $521.31M | $94.19B |
| Net income (latest FY) | -$23.36M | $26.80B |
| Net margin | -4.5% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 612 | 984 |
JOHNSON & JOHNSON is 100.2x more valuable than Mirum Pharmaceuticals, Inc. by market capitalization ($574.10 B vs $5.73 B).
In their latest fiscal years, Mirum Pharmaceuticals, Inc. reported $521.31M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Mirum Pharmaceuticals, Inc. and JOHNSON & JOHNSON, or browse the full rankings.